JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback